These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 14624375

  • 21. Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
    Tural C, Solà R, Rubio R, Santín M, Planas R, Quereda C, Berenguer J, Montes-Ramírez M, Clotet B, CORAL-1 study group.
    J Viral Hepat; 2007 Oct; 14(10):704-13. PubMed ID: 17875005
    [Abstract] [Full Text] [Related]

  • 22. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
    [Abstract] [Full Text] [Related]

  • 23. Relating the outcome of HCV infection and different host SNP polymorphisms in a Majorcan population coinfected with HCV-HIV and treated with pegIFN-RBV.
    Matas M, Picornell A, Cifuentes C, Payeras A, Homar F, González-Candelas F, López-Labrador FX, Moya A, Ramon C, Castro JA.
    Int Microbiol; 2014 Mar; 17(1):11-20. PubMed ID: 25296442
    [Abstract] [Full Text] [Related]

  • 24. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L, Nuñez M, Mariño A, Alcocer F, Bonet L, García-Samaniego J, López-Serrano P, Cordero M, Portu J, Soriano V.
    AIDS; 2008 Jan 02; 22(1):15-21. PubMed ID: 18090387
    [Abstract] [Full Text] [Related]

  • 25. Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV.
    Rivero-Juarez A, Mira JA, Camacho A, Neukam K, Perez-Camacho I, Caruz A, Macias J, Torre-Cisneros J, Pineda JA, Rivero A.
    Infection; 2013 Feb 02; 41(1):21-6. PubMed ID: 23065463
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirin.
    Moreno A, Bárcena R, García-Garzón S, Muriel A, Quereda C, Moreno L, Mateos ML, Fortún J, Martín-Dávila P, García M, Blesa C, Otón E, Moreno A, Moreno S.
    J Hepatol; 2005 Nov 02; 43(5):783-90. PubMed ID: 16084622
    [Abstract] [Full Text] [Related]

  • 28. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.
    Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, Tawil AA, Fehr JJ, Khalifa Kel S, Madwar MM, Koziel MJ.
    Hepatology; 2004 Jun 02; 39(6):1721-31. PubMed ID: 15185314
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts.
    Avidan NU, Goldstein D, Rozenberg L, McLaughlin M, Ferenci P, Masur H, Buti M, Fauci AS, Polis MA, Kottilil S.
    J Acquir Immune Defic Syndr; 2009 Dec 01; 52(4):452-8. PubMed ID: 19797971
    [Abstract] [Full Text] [Related]

  • 31. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.
    Soriano V, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, de los Santos I, San Joaquín I, Echeverria S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola J, Blanco F, Martin-Carbonero L, García-Samaniego J, Nuñez M, PRESCO Study Group.
    Antivir Ther; 2007 Dec 01; 12(4):469-76. PubMed ID: 17668555
    [Abstract] [Full Text] [Related]

  • 32. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
    Zeuzem S, Schmidt JM, Lee JH, von Wagner M, Teuber G, Roth WK.
    Hepatology; 1998 Jul 01; 28(1):245-52. PubMed ID: 9657119
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes.
    Maida I, Martin-Carbonero L, Sotgiu G, Vispo E, Barreiro P, Gonzalez-Lahoz J, Soriano V.
    J Viral Hepat; 2010 Dec 01; 17(12):866-71. PubMed ID: 20088891
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders.
    Talal AH, Ribeiro RM, Powers KA, Grace M, Cullen C, Hussain M, Markatou M, Perelson AS.
    Hepatology; 2006 May 01; 43(5):943-53. PubMed ID: 16761329
    [Abstract] [Full Text] [Related]

  • 39. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
    Ferraro D, Bonura C, Giglio M, Di Stefano R, Almasio PL, Di Marco V, Craxì A, Cacciola I, Squadrito G, Raimondo G.
    J Biol Regul Homeost Agents; 2003 May 01; 17(2):172-5. PubMed ID: 14518718
    [Abstract] [Full Text] [Related]

  • 40. Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients.
    Grubczak K, Grzeszczuk A, Groth M, Hryniewicz A, Kretowska-Grunwald A, Flisiak R, Moniuszko M.
    Viruses; 2021 Jul 25; 13(8):. PubMed ID: 34452314
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.